- Home
- IMTX vs AUTL Comparison
IMTX vs AUTL Comparison
Compare IMTX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTX
- AUTL
- Stock Information
- Founded
- IMTX N/A
- AUTL 2014
- Country
- IMTX Germany
- AUTL United Kingdom
- Employees
- IMTX N/A
- AUTL N/A
- Industry
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMTX Health Care
- AUTL Health Care
- Exchange
- IMTX Nasdaq
- AUTL Nasdaq
- Market Cap
- IMTX 653.9M
- AUTL 625.4M
- IPO Year
- IMTX N/A
- AUTL 2018
- Fundamental
- Price
- IMTX $6.33
- AUTL $1.78
- Analyst Decision
- IMTX Strong Buy
- AUTL Strong Buy
- Analyst Count
- IMTX 4
- AUTL 5
- Target Price
- IMTX $14.67
- AUTL $9.12
- AVG Volume (30 Days)
- IMTX 537.7K
- AUTL 2.6M
- Earning Date
- IMTX 08-13-2025
- AUTL 08-12-2025
- Dividend Yield
- IMTX N/A
- AUTL N/A
- EPS Growth
- IMTX N/A
- AUTL N/A
- EPS
- IMTX N/A
- AUTL N/A
- Revenue
- IMTX $152,823,253.00
- AUTL $29,934,000.00
- Revenue This Year
- IMTX N/A
- AUTL $472.28
- Revenue Next Year
- IMTX $1.92
- AUTL $114.92
- P/E Ratio
- IMTX N/A
- AUTL N/A
- Revenue Growth
- IMTX 83.61
- AUTL 185.17
- 52 Week Low
- IMTX $3.30
- AUTL $1.11
- 52 Week High
- IMTX $13.09
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- IMTX 52.73
- AUTL 29.40
- Support Level
- IMTX $5.56
- AUTL $1.83
- Resistance Level
- IMTX $6.50
- AUTL $2.52
- Average True Range (ATR)
- IMTX 0.35
- AUTL 0.17
- MACD
- IMTX -0.07
- AUTL -0.08
- Stochastic Oscillator
- IMTX 62.10
- AUTL 13.68
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.